Top Markets
Coin of the day
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rang in Aktien #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Aktienkurs
$2.70
Zuletzt synchronisiert: 2023-05-17
Marktkapitalisierung
$4.13M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Graybug Vision, Inc. (GRAY)

Kategorie

Dividendenhistorie für Graybug Vision, Inc. (GRAY)
Graybug Vision, Inc. (Aktienkürzel: GRAY) zahlte insgesamt 0 Dividenden.
Die Summe aller Dividenden (angepasst an Aktiensplits) beträgt: 0.00
Dividendenrendite (TTM): 0
Dividendenzahlungen für Graybug Vision, Inc. (GRAY) von 2026 bis 2026
Jährliche Dividendenzahlungen
Jahr Dividende (angepasst an Aktiensplits) ändert
Nicht genügend Daten für die angegebenen Daten.
Liste aller Dividendenzahlungen
Jahr Dividende ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenzahlungen ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Dividendenzahlungen Land
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
29.00%
BE